Amicus Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) announces that CEO John F. Crowley will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on June 10, 2020, at 8:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Amicus Therapeutics (Nasdaq: FOLD) announces that CEO John F. Crowley will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on June 10, 2020, at 8:00 a.m. ET. This event will take place virtually, allowing interested parties to access a live audio webcast via the company's Investor Relations page. Amicus Therapeutics focuses on developing innovative medicines for rare metabolic diseases, furthering its commitment to patients through a robust pipeline of advanced therapies. For details, visit www.amicusrx.com.
Details
News Market Reaction – FOLD
The recorded move for FOLD in the trading session of this news was -0.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CRANBURY, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference, being held virtually on Wednesday, June 10, 2020 at 8:00 a.m. ET.
A live audio webcast of the presentation can also be accessed via the Investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn.
CONTACTS:
Investors/Media:
Amicus Therapeutics
Andrew Faughnan
Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
FOLD–G
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.